SAN DIEGO, CA -- (Marketwired) -- --
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects revenues in the fourth quarter of 2016 to be in the range of
We appreciate your efforts to improve patient care, physician services, and laboratory efficiency. We know that you will appreciate the value that Quidel brings in delivering diagnostics that do not sacrifice accuracy or ease-of-use. Please explore this site for helpful resources and how you can contact us for further support.